Small-cap biotech news flow on Tuesday centred on partnerships and validation rather than clinical trial readouts, with one company converting a long-standing letter of intent into a binding revenue pathway, two others securing external certification and independent scientific backing for their platforms, and a fourth completing a major patient recruitment milestone tied to NHS rollout plans.
Hemogenyx signs binding Estonia deal for CAR-T therapy
Hemogenyx Pharmaceuticals (LSE:HEMO), down 1.79% at 631.0p, has signed a definitive collaboration agreement with Estonian cell therapy company Cellin Technologies OÜ to manufacture and commercialise its CAR-T candidate HG-CT-1 for relapsed or refractory acute myeloid leukaemia under Estonia's Hospital Exemption framework. The deal converts a non-binding letter of intent dating from September 2025 into binding commitments, and the company describes it as its first potential near-term revenue opportunity, notable for a clinical-stage biotech still years from conventional market authorisation in most jurisdictions.
Under the Hospital Exemption route, advanced therapies not yet commercially authorised can be administered under a doctor's responsibility, subject to sign-off from Estonia's State Agency of Medicines, with treatment costs potentially reimbursed through the Estonian Health Insurance Fund. Hemogenyx will transfer its manufacturing know-how to Cellin's GMP-compliant Tallinn facility over roughly four months, followed by an approximately 90-day regulatory review. Cellin becomes the exclusive manufacturing and operational partner in Estonia for five years, managing the regulatory dossier and reimbursement coordination while patients are treated at Taastava Kirurgia Kliinik AS in Tallinn; Hemogenyx retains full IP ownership and all rights outside Estonia, with the two parties splitting net operating margin per patient after direct therapy costs.
"The signing of this definitive agreement with Cellin transforms our plans in Estonia from intent into execution, a clear, binding path to delivering HG-CT-1 to patients," said Dr Vladislav Sandler, chief executive of Hemogenyx Pharmaceuticals.
The company was careful to flag that no minimum patient numbers or revenue are guaranteed, with completion of tech transfer, regulatory authorisation and reimbursement approval all still outstanding. But the shift from letter of intent to binding contract matters for the investment case regardless of near-term revenue scale: it gives Hemogenyx a live regulatory pathway that sidesteps the far longer timelines of full EMA or FDA approval, and establishes a template, sharing margin with a manufacturing partner in a smaller EU jurisdiction, that could be replicated elsewhere if the Tallinn programme proves the model works.
Verici Dx wins Olink certification for proteomics services
Verici Dx (LSE:VRCI), up 11.111% at 0.25p, has been designated an Olink Certified Service Provider under Thermo Fisher's Life Sciences Solutions arm. The AIM-listed diagnostics developer, whose lead product Tutivia targets early detection of acute rejection after kidney transplant, can now run Olink-based proteomics assays at its CAP-certified, CLIA-accredited laboratory, spanning biomarker discovery, algorithm development, validation and clinical use.
The certification process required Verici Dx to complete rigorous training and annual concordance testing, and the company positions its offering as broader than standard sample analysis, combining bioinformatics, a CAP/CLIA/ISO-compliant quality framework and multi-omics expertise across genomics, transcriptomics and proteomics. The capability will serve both third-party client work and the company's own protein biomarker pipeline.
For a small diagnostics company, external accreditation from a platform tied to Thermo Fisher carries commercial weight beyond the science: it signals to potential pharma and academic clients that Verici Dx's lab meets an industry benchmark, potentially opening a fee-for-service revenue stream that runs alongside, and helps fund, its core transplant diagnostics development.
Genedrive completes NICU recruitment for hearing-loss test
genedrive (AIM:GDR), up 4.348% at 1.2p, has completed patient recruitment for its PALOH-UK programme, screening close to 6,000 babies across 14 UK neonatal intensive care units. The company's Genedrive MT-RNR1 ID Kit identifies a genetic variant that raises the risk of permanent deafness in newborns exposed to a common antibiotic used in neonatal care.
The programme, funded by the National Institute for Health and Care Research and the UK Government Office for Life Sciences, was designed to generate real-world evidence for NICE, which had granted the test conditional recommendation under its Early Value Assessment pathway. That test has now exited early assessment and moved into full NICE technology appraisal following ministerial referral, with NHS England targeting a tender notice by 1 January 2027 and a go-live date of July 2027. "To date, more than 13,000 babies have been tested using the Genedrive MT-RNR1 ID Kit in the UK and internationally, with over 40 babies avoiding aminoglycoside exposure and the risk of lifelong deafness," said Gino Miele, chief executive of genedrive.
Completing recruitment removes a key dependency ahead of the clinical cohort analysis now underway, and sets a concrete runway toward NHS-wide adoption, a tender and go-live timeline that, if it holds, would give genedrive its clearest line of sight yet to a national reimbursed rollout for its flagship test.
Independent study backs Parsortix CTC tech in brain cancer
CelLBxHealth (AIM:CLBX), down 1.43% at 1.3307p, said a peer-reviewed study has demonstrated diagnostic potential for its Parsortix platform in glioblastoma, the most common aggressive brain tumour in adults. Researchers at Fondazione Pisana per la Scienza and Ospedali Riuniti di Livorno in Italy used Parsortix to enrich circulating tumour cells from blood samples of 27 glioblastoma patients alongside healthy controls and non-cancerous brain lesion cases.
The study proposed the first numerical CTC threshold for glioblastoma, with more than four CTCs per 5 mL of blood distinguishing primary patients from healthy controls at 80% sensitivity and 77.3% specificity. The Parsortix-enriched cells carried tumour-related mutations and chromosomal changes matching those found in tumour tissue, while radionecrosis and lymphoma samples yielded no detectable CTCs. "This study provides compelling independent evidence, aligned with our recently presented internal research, that Parsortix-enriched CTCs can provide biologically relevant information in GBM," said Lavanya Sivapalan, adding that "glioblastoma remains one of the most difficult cancers to monitor, as repeat tissue sampling requires invasive neurosurgery and imaging can be difficult to interpret, particularly when assessing suspected recurrence."
Third-party validation from an independent Italian research group strengthens CelLBxHealth's case that Parsortix has utility beyond the liquid biopsy applications it is best known for, opening a path toward monitoring a cancer where safer, repeatable testing options are scarce and clinical need is acute.
